You are here

Global $5.6 Bn Parkinson's Disease Drugs Markets, 2018-2019 & 2024 - Supportive initiatives from Government and Other Organizations & Exhaustive Pipeline and Increasing Clinical Trials

DUBLIN, April 8, 2019 /PRNewswire/ -- The "Global Parkinson's Disease Drugs Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

Global Parkinson's Disease Drugs Market is Expected to Witness a CAGR of 7.2% to Reach Revenue of $5,614.6 Million by 2024

Huge patient pool and rising rate of diagnosis are the significant factors driving the market growth. The Parkinson's Disease Foundation has stated that nearly 10 million people are suffering from this disorder globally. The highest frequency of this disorder is observed in developed countries, and in the US, almost 60,000 new cases are reported annually.

PD is an idiopathic disease for which the cause of the occurrence is still unknown, hence only symptomatic drugs are available in the market for the treatment. Furthermore, the disorder is diagnosed in the final stages when the majority of the cells that produce dopamine lose their functionality. This is demanding more innovative and novel drugs for the treatment.

Regional Analysis

North America accounts for the largest share of the market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by Europe, with Germany being the major contributor to the market growth.

Drug Class Analysis
Based on drug classes, the market is segmented into levodopa, MAO-B inhibitors, COMT inhibitors, dopamine agonists, anticholinergics, and others. Levodopa is the most attractive drug in the market owing to its highly effective treatment in controlling the motor symptoms throughout the stages of Parkinson's disease. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa. This is the original drug indicated explicitly for dyskinesia, which is technologically advanced with the long-term use of levodopa.

Key Players
The major players in the market include Novartis, Roche, AbbVie, Teva Pharmaceutical, Pfizer, STADA Arzneimittel AG, GSK, Valeant, Merck & Co. Inc., and Amneal Pharmaceuticals Inc.

Competitive Analysis

New product launch and collaboration are the primary strategies being followed by the market players to maintain their leadership and strengthen the market position. In January 2015, Neuropore Therapies Inc. and UCB S.A. signed a commercialization agreement for NPT200-11. Recently, Impax Pharmaceuticals' RYTARY and AbbVie's DUOPA received the US FDA approval for the treatment of Parkinson's disease. Other strategies include business partnerships, mergers & acquisitions, and a multifaceted pipeline. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa.

Key Topics Covered:

1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand:
1.1.2 Pharmaceutical spending region wise
1.1.3 R&D pipeline in pharmaceutical industry
1.1.4 Top pharma drugs by sales in 2017 ($Million)
1.2 Total Addressable Market

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition - Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of Parkinson Diseases Market
3.4 Related Markets
3.4.1 Neurosurgical Devices
3.4.2 Neurointerventional Devices
3.4.3 Over the counter drugs (OTC)

4 Market Outline
4.1 Pipeline Products of Parkinson Diseases Drugs
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis

5 Market Characteristics
5.1 Market Dynamics of Parkinson Diseases Market
5.1.1 Drivers
5.1.1.1 Increasing Aging Population
5.1.1.2 Increasing Prevalence of Parkinson Diseases
5.1.2 Opportunities
5.1.2.1 Supportive initiatives from government and other organizations
5.1.2.2 Exhaustive Pipeline and Increasing Clinical Trials
5.1.3 Restraints
5.1.3.1 Expiry of patents for blockbuster drugs and availability of generic drugs
5.1.3.2 Complex drug development process
5.1.4 DRO - Impact Analysis
5.1.5 Key Stakeholders

6 Drug Type: Market Size and Analysis
6.1 Overview
6.2 Levodopa
6.3 Dopamine agonists
6.4 MAO-B inhibitors
6.5 COMT Inhibitor
6.6 Anticholinergics
6.7 Others

7 Regions: Market Size and Analysis

8 Competitive Landscape

9 Vendor Profiles
9.1 Novartis AG
9.2 GlaxoSmithKline plc
9.3 F.Hoffmann-La Roche Ltd.
9.4 AbbVie Inc.
9.5 Merck & Co., Inc.
9.6 Teva Pharmaceutical Industries Ltd.
9.7 Valeant Pharmaceuticals International Inc.

10 Companies to Watch For
10.1 Boehringer Ingelheim GmbH
10.2 Amneal Pharmaceuticals, Inc.
10.3 Wockhardt
10.4 STADA Arzneimittel AG
10.5 Pfizer Inc.
10.6 Sun Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/ieaulf

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-5-6-bn-parkinsons-disease-drugs-markets-2018-2019--2024---supportive-initiatives-from-government-and-other-organizations--exhaustive-pipeline-and-increasing-clinical-trials-300826159.html

SOURCE Research and Markets